- Trial phase
- Phase 3
- Time to market
- If the Phase 3 REGAL trial succeeds, the earliest potential regulatory submission (BLA) would follow the topline readout in Q4 2026, with an FDA review timeline of roughly 10-12 months thereafter, putting a potential approval in late 2027 or early 2028 at the earliest.
- Why 8/10
- The next hard, dated catalyst is the topline Phase 3 REGAL overall survival readout expected in Q4 2026 (within ~2 months). This is a make-or-break binary event for SELLAS's lead and most valuable asset at a company that is pre-revenue and whose market cap is overwhelmingly driven by this single drug, justifying an 8 on the impact scale.
Watch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.
Price Chart
Executive Summary
Galinpepimut-S (GPS) is SELLAS Life Sciences' lead asset, a WT1-targeting peptide cancer immunotherapy in a pivotal Phase 3 REGAL trial for acute myeloid leukemia. On October 28, 2026, the company announced the trial reached the 80th death event triggering final analysis, with topline overall survival results expected in Q4 2026. The stock is a high-risk binary bet: STAT News has predicted failure, and a securities investigation over delayed disclosure of the 80th event adds legal overhang. However, the trial passed futility, major institutions accumulated large positions in Q2 2026, and analyst price targets ($30-$35) imply substantial upside if the data are positive.
How It Works
A cancer vaccine (peptide immunotherapy) that trains the immune system's T-cells to recognize and attack cancer cells displaying the Wilms Tumor 1 (WT1) protein, which is overexpressed in many blood cancers and solid tumors. It uses four peptide fragments of the WT1 protein to stimulate both CD8+ "killer" T-cells and CD4+ "helper" T-cells.
Trial Status
The pivotal Phase 3 REGAL trial (NCT04229979) is an event-driven overall survival study in 126 acute myeloid leukemia (AML) patients in second complete remission (CR2), randomized to galinpepimut-S versus investigator's choice of best available therapy. The trial passed a pre-specified interim futility analysis in January 2025, with the Independent Data Monitoring Committee recommending continuation. On October 28, 2026, SELLAS announced the trial reached the 80th patient death (the pre-specified event count triggering final analysis). The company will proceed with database lock, unblinding, and statistical analysis, with topline primary endpoint results expected in Q4 2026.
The Two-Sided Case
Upcoming Catalysts
- Topline Phase 3 REGAL overall survival results expected Q4 2026 (within ~2 months)
- Q3 2026 earnings report scheduled November 10, 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
SELLAS Life Sciences Group, Inc. Press Release SLS ·Originating report